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Background. Respiratory syncytial virus (RSV) causes significant mortality in patients with hematological
diseases, but diagnosis and treatment are uncertain.
Methods. We retrospectively identified RSV-infected patients with upper or lower respiratory tract infection
(RTI) by culture, antigen testing, and polymerase chain reaction from November 2002 through April 2007. Patients
with severe immunodeficiency (SID; defined as transplantation in the previous 6 months, T or B cell depletion
in the previous 3 months, graft-versus-host disease [grade, 2], leukopenia, lymphopenia, or hypogammaglob-
ulinemia) preferentially received oral ribavirin, intravenous immunoglobulin, and palivizumab. The remaining
patients with moderate immunodeficiency (MID) preferentially received ribavirin and intravenous im-
munoglobulin.
Results. We identified 34 patients, 22 of whom had upper RTI (10 patients with MID and 12 with SID) and
12 of whom had lower RTI (2 with MID and 10 with SID). Thirty-one patients were tested by polymerase chain
reaction (100% of these patients had positive results; median RSV load, 5.46 log10 copies/mL), 30 were tested by
culture (57% had positive results), and 25 were tested by antigen testing (40% had positive results). RSV-attributed
mortality was 18% (6 patients died) and was associated with having 2 SID factors ( ), lower RTI (Pp .04 Pp
), and preengraftment ( ). Among 12 patients with MID (7 of whom received treatment), no progression.01 Pp .012
or death occurred. Nine patients with SID and upper RTI received treatment (7 patients received ribavirin,
intravenous immunoglobulin, and palivizumab); infection progressed to the lower respiratory tract in 2 patients,
and 1 patient died. Ten patients with SID and lower RTI were treated, 5 of whom died, including 4 of 6 patients
who received ribavirin, intravenous immunoglobulin, and palivizumab. The duration of RSV shedding correlated
with the duration of symptoms in patients with SID but exceeded symptom duration in patients with MID
( ).P ! .05
Conclusions. Lower RTI, 2 SID criteria, and preengraftment are risk factors for RSV-attributed mortality.
Polymerase chain reaction may optimize diagnosis and monitoring. Oral ribavirin therapy seems safe, but trials
are needed to demonstrate its efficacy.
Respiratory syncytial virus (RSV) causes significant
morbidity and mortality in adult patients with hema-
tological diseases when upper respiratory tract infection
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(RTI) progresses to lower RTI [1, 2]. Progression from
upper to lower RTI has been estimated to develop in
up to 50% of patients who have received chemotherapy
for leukemia or undergone hematopoietic stem cell
transplantation (HSCT), with mortality rates of 20%–
60% [3, 4]. The frequency of progression to lower RTI
may be associated with lymphopenia, allogeneic HSCT,
graft-versus-host disease, and diagnosis within 1 month
after transplantation [2, 3, 5, 6], justifying delaying
HSCT [7]. Detection of RSV by antigen testing, culture,
and RT-PCR is now available, but these tests have rarely
been compared in hematology clinics.
Treatment of RSV infection in patients with hema-
tological disease includes ribavirin aerosol inhalation,
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Table 1. Baseline characteristics of study patients.
Characteristic
HSCT recipients
(n p 27)
All patients
(n p 34)
Sex
Male 17 (63) 20 (59)
Female 10 (37) 14 (41)
Age, mean years  SD 41.9  17 41.7  16.7
Underlying disease
Leukemia
Acute lymphocytic 9 (33) 11 (32)
Acute myelogenous 5 (18.5) 6 (18)
Chronic myelogenous 2 (7) 2 (6)
Non-Hodgkin lymphoma 5 (18.5) 6 (18)
Hodgkin disease 1 (4) 1 (3)
Multiple myeloma 3 (11) 3 (9)
Aplastic anemia 1 (4) 3 (9)
Other 1 (4) 2 (6)
Underlying disease state at RSV diagnosis
Remission 14 (52) 20 (59)
Minimal residual disease 3 (11) 3 (9)
Persistent or relapse 8 (30) 9 (26)
Unclear 2 (7) 2 (6)
T cell depletiona 7 (26) 9 (26)
Donor type
Autologous 3 (11) …
Allogeneic
Matched, related 14 (52) …
Matched, unrelated 5 (18) …
Mismatched, related 4 (15) …
Mismatched, unrelated 1 (4) …
Conditioning regimen
Myeloablative 18 (67) …
Reduced intensity 9 (33) …
Time from receipt of HSCT to engraft-
ment, median days (IQR) 14 (13–20.5) …
Time from receipt of HSCT to diagnosis
of RSV infection, median days (IQR) 210 (127–475) …
Graft-versus-host disease 13 (48) …
Immunsuppressive therapy
Cyclosporin 10 (37) …
Cyclosporin and corticosteroids 6 (22) …
Cyclosporin, corticosteroids, and
cellcept 6 (22) …
NOTE. Data are no. (%) of patients, unless otherwise indicated. HSCT,
hematopoietic stem cell transplant; IQR, interquartile range; RSV, respiratory
syncytial virus.
a T cell depletion is defined as treatment or conditioning regimen with anti–
T cell globulin, anti–CD3 antibody, anti-CD52, and/or T cell–depleted HSCT.
intravenous immunoglobulin (IVIG), RSV hyperimmunoglob-
ulin, or palivizumab (a monoclonal IgG that neutralizes RSV
by binding the envelope protein F) [1, 2, 8]. These treatments
have been available for more than a decade, but clear evidence
of efficacy is lacking. Aerosolized ribavirin might improve out-
come when administered early, before lower RTI develops [6,
9, 10]. However, most patients are infected as outpatients—
before or after hospitalization for chemotherapy or HSCT—
when RSV circulates in the community. Oral ribavirin has a
bioavailability of 30%–74% [11] and was successfully admin-
istered to 4 patients with upper RTI [12]. Aerosolized or in-
travenous ribavirin has been combined with IVIG or RSV hy-
perimmunoglobulin to treat RSV infection in pediatric patients
and adult HSCT recipients, but the efficacy of these treatments
has not been established [13, 14]. Palivizumab is registered for
the treatment and prophylaxis of RSV bronchiolitis in small
infants, but high costs and uncertain efficacy question its use
in adult patients with hematological diseases [15]. We proposed
a management scheme according to the presumed risk of im-
munodeficiency [16]. Here, we report the retrospective analysis
of RSV infection in the patients with hematological diseases
and review the literature.
METHODS
Setting. The hematology unit at the University Hospital Basel
(Basel, Switzerland) is a referral center for adults (age, 18
years) receiving myeloablative chemotherapy and undergoing
autologous and allogeneic HSCT. From February 2002 through
April 2007, 212 myeloablative chemotherapy treatments and
402 transplantations (119 autologous and 283 allogeneic) were
performed. A high-resolution CT is routinely done in cases
involving neutropenic fever and respiratory symptoms and is
performed weekly when antiviral or antifungal agents are ad-
ministered. In cases of suspected respiratory infection, bron-
choalveolar lavage (BAL) is performed within 24 h after onset
of symptoms.
Patients and definitions. A retrospective chart review was
performed for all inpatients and outpatients who received di-
agnoses of symptomatic RSV infection during the period No-
vember 2002–April 2007. Upper RTI was defined as detection
of RSV in upper respiratory secretions, together with symptoms
involving the upper respiratory tract (nose and throat), ac-
cording to Ljungman et al. [3]. Lower RTI was defined as the
presence of either hypoxia or pulmonary infiltrates, together
with identification of RSV in upper or lower respiratory se-
cretions and exclusion of other causes [3].
Severe immunodeficiency (SID) was defined as HSCT 6
months prior to diagnosis of RSV infection, T cell depletion
3 months prior to diagnosis, B cell depletion 3 months
prior to diagnosis, graft-versus-host disease (grade, 2), leu-
kopenia (leukocyte count,  cells/L, lymphopenia92.0 10
(lymphocyte count,  cells/L), or hypogammaglob-90.1 10
ulinemia (immunoglobulin level, 6.5 g/L). Moderate im-
munodeficiency (MID) was defined as HSCT 16 months prior
to diagnosis of RSV infection, graft-versus-host disease (grade,
!2), leukocyte count 1 cells/L, lymphocyte count92.0 10
1 cells/L, receipt of maintenance immunosuppressive90.1 10
drugs, or T cell or B cell depletion 13 months prior to diagnosis
of RSV infection. RSV-attributable mortality was defined as
death due to respiratory failure, with no cause other than RSV
pneumonia identified.
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Table 2. Characteristics of patients according to immunodeficiency.
Variable
No. (%)
of patients
Moderate immunodeficiency
HSCT 6 months prior to diagnosis of RSV infection 7 (58)
Immunosuppressive treatment 4 (33)
T cell depletion 13 months prior to diagnosis of RSV infection 4 (33)
Severe immunodeficiency
Acute GVHD (grade, 2) 13 (59)
HSCT !6 months prior to diagnosis of RSV infection 9 (41)
Leukopenia (leukocyte count, 2.0  109 cells/L) 6 (27)
Lymphopenia (lymphocyte count, 0.1  109 cells/L) 6 (27)
T cell depletion !3 months prior to diagnosis of RSV infection 5 (23)
Preengraftment 4 (18)
Hypogammaglobulinemia (immunoglobulin level, !6.5 g/L) 3 (14)
B cell depletion !3 months prior to diagnosis of RSV infection 1 (5)
NOTE. Data are for 12 patients with moderate immunodeficiency and 22 patients with
severe immunodeficiency. GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell
transplantation; RSV, respiratory syncytial virus.
Virological techniques. RSV infection was diagnosed by
testing for antigen, by isolation in tissue culture, and/or by
quantitative RT-PCR after specimen arrival at the laboratory.
For microbiological diagnosis, nasopharyngeal aspirate speci-
mens, swab specimens (for upper RTI), and BAL specimens
were obtained from the site of clinically active infection (for
lower RTI). For a follow-up examination, serial nasal secretion
specimens were obtained from 19 patients. For RSV isolation,
specimens were collected in 3 mL of viral transport media and
then inoculated onto shell vials for tissue cultures (Madin-
Darby canine kidney cells, rhesus monkey kidney cells, human
lung carcinoma cells, and human fetal diploid fibroblast cells).
RSV was identified by the cytopathic effect and diagnosed by
staining with a fluorescein-conjugated monoclonal antibody
(Virion). For the RSV antigen test, the NOW RSV Test Kit
(Binax) was used. RSV RT-PCR was performed according to a
previously published protocol detecting type A and type B in
separate reactions [17]. The limit of detection was 1000 copies/
mL.
Antiviral treatment. Stratified treatment was recom-
mended according to presumed immunodeficiency and site of
infection, as published elsewhere [16]. Patients with MID and
upper or lower RTI received oral ribavirin (initiated with 10
mg/kg as a loading dose and then increased to 400 mg 3 times
daily on day 2 and 600 mg 3 times daily on day 3) plus IVIG
(0.5 g/kg weekly). Patients with SID and upper RTI were treated
with the same ribavirin regimen as that for patients with MID
and upper or lower RTI, IVIG (0.5 g/kg every other day), and
palivizumab (15 mg/kg administered as a single intravenous
dose). Patients with SID and lower RTI received the same ri-
bavirin regimen as that for the other patients and IVIG (0.5 g/
kg every other day). The use of palivizumab in patients with
SID and lower RTI was based on the decision of the treating
physician.
Switching to intravenous administration of ribavirin was only
done in patients receiving mechanical ventilation, using the
same dosing as that for oral administration. Treatment was
discontinued when patients were asymptomatic and RSV was
no longer detectable by RT-PCR.
Infection control and supportive care measures. Hospi-
talized patients with signs of RTI were isolated in single rooms
with laminar air flow. Outpatients were seen in single rooms
in a different wing of the hospital. Isolation precautions in-
cluded hand hygiene with an alcohol-based hand rub, gloves,
gowns, and protective goggles [16]. Contact isolation was dis-
continued when patients were asymptomatic and RSV was no
longer detectable by RT-PCR.
Statistical analysis. All statistical analyses were performed
with SPSS, version 14.0 (SPSS). Quantitative RSV RT-PCR was
compared with antigen testing and culture using a receiver
operating characteristics curve. Study groups were compared
by Mann-Whitney U test or Wilcoxon signed rank sum test.
Categorical variables were compared by x2 test or Fisher’s exact
test. A 2-sided P value !.05 was considered to be significant.
RESULTS
Patient characteristics. From 2002 through 2007, 34 patients
were diagnosed with RSV infection at our hospital; all cases
occurred from November through April, when RSV infection
is prevalent in Switzerland [18]. Patient characteristics at RSV
diagnosis are listed in table 1. Most patients had leukemia,
which was in remission in approximately one-half of these
patients. HSCT was performed for 79% of the patients, 52%
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Figure 1. Comparison of respiratory syncytial viral (RSV) PCR with
culture and antigen testing. A, Box plots of quantitative RSV PCR results
for patients with positive or negative culture and antigen test results. B,
Receiver operating characteristic curve of the RSV RT-PCR to predict
culture results (area under the curve [AUC], 0.92; 95% CI, 0.84–1.0). C,
Receiver operating characteristic curve of the RSV RT-PCR to predict
antigen test results (AUC, 0.92; 95% CI, 0.83–1.0).
of whom had a matched, related donor. Eighteen individuals
(53%) presented as outpatients. At the time of RSV diagnosis,
upper RTI was diagnosed in 22 patients (65%), and lower RTI
was diagnosed in 12 patients (35%). All of the patients who
had received a diagnosis of lower RTI had a new infiltrate on
CT, with hypoxia in 3 patients (25%).
Characteristics according to immunodeficiency. Char-
acteristics of patients according to immunodeficiency are
shown in table 2. MID was diagnosed in 12 patients, with 5
patients (42%) fulfilling 2 criteria. SID was diagnosed in 22
patients; 13 patients (59%) fulfilled 2 criteria, and 6 (27%)
fulfilled 3 criteria.
Diagnostic results. At diagnosis, RSV was detected in nasal
aspirate specimens from 27 patients and in BAL specimens from
7 patients. RSV-specific RT-PCR was performed for samples
from 31 patients (91%), and all of the results were positive.
Median RSV load at diagnosis was 5.46 log10 copies/mL (in-
terquartile range [IQR], 4.52–6.75 log10 copies/mL), the median
RSV load in RSV-positive nasal aspirate specimens was 5.46
log10 copies/mL (IQR, 4.54–6.61 log10 copies/mL), and the me-
dian RSV load in RSV-positive BAL specimens was 5.58 log10
copies/mL (IQR, 3.98–6.57 log10 copies/mL). RSV subtypes
were available for 30 patients; 16 had subtype A, and 14 had
subtype B, without statistically significant differences in RSV
load. Culture was performed for samples from 30 patients (88%
of total patients tested), and results were positive for samples
from 17 (57%) of these 30 patients. Antigen tests were per-
formed for samples from 25 patients (74%), and the results
were positive for samples from 10 (40%) of these 25 patients.
In total, 105 specimens (84 nasal aspirate specimens and 21
BAL specimens) were obtained from the 34 patients. RT-PCR
was conducted for 101 specimens, and the results were positive
for 70 (69%) of these specimens. Culture was performed for
74 samples, and the results were positive for 27 (36%) of these
samples. Antigen tests were performed for 60 specimens, and
results were positive for 12 (20%) of these specimens. For 47
specimens, all 3 tests were performed. RT-PCR results were
positive for 32 samples (68%), and results of both culture and
RT-PCR were positive for 14 samples (30%). Results of both
antigen test and RT-PCR were positive for 11 specimens (23%).
All culture- and/or antigen-positive samples were also RT-PCR
positive. Among these 47 specimens, the median RSV load was
6.9 log10 copies/mL (IQR, 6.1–7.6 log10 copies/mL) in culture-
and RT-PCR–positive specimens and 7.3 log10 copies/mL (IQR,
6.3–7.7 log10 copies/mL) antigen test– and RT-PCR–positive
specimens (figure 1A). For RSV isolation, receiver operating
characteristics curve analysis of the quantitative RSV RT-PCR
predicted optimal sensitivity and specificity at 5.21 log10 copies/
mL (area under the curve, 0.92; 95% CI, 0.84–1.0). Excluding
2 outliers, the threshold for a positive culture result was an
RSV load 5.32 log10 copies/mL (figure 1B). For RSV antigen
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Figure 2. Respiratory syncytial viral (RSV) load in serial nasal swab specimens. Serial quantitative RT-PCR results (log10 copies/mL) are shown for
19 patients over a maximal 34 days. Patients with severe immunodeficiency ( ) are represented by white diamonds, and patients with moderatenp 11
immunodeficiency ( ) are represented by black triangles.np 8
detection, optimal sensitivity and specificity was reached at an
RSV load of 5.53 log10 copies/mL (area under the curve, 0.92;
95% CI, 0.83–1.01). Excluding 1 outlier, the threshold for a
positive antigen test result was an RSV load5.56 log10 copies/
mL (figure 1C).
Site of infection, treatment, and outcome. Upper RTI was
identified in 10 patients with MID, 5 of whom did not receive
treatment. Five patients with MID were treated with oral ri-
bavirin (median duration of therapy, 14 days; range, 5–21 days)
and IVIG (1–3 doses). No progression to lower RTI and no
deaths occurred. Lower RTI was identified in 2 patients with
MID. Both received oral ribavirin (for 8 and 16 days, respec-
tively), one received IVIG, and both survived. Upper RTI was
identified in 12 patients with SID. Three were not treated, 3
received ribavirin and IVIG, and all survived. The remaining
6 patients with SID received ribavirin, IVIG, and palivizumab,
but infection progressed to the lower respiratory tract in 2
patients, and 1 patient died. Treatment with ribavirin was ap-
plied for a median duration of 16 days (range, 4–64 days).
Median duration of IVIG treatment was 2 days (range, 1–6
days). Lower RTI was identified in 10 patients with SID (1 was
treated with IVIG only, 2 were treated with ribavirin and IVIG,
and 7 were treated with ribavirin, IVIG, and palivizumab). Five
patients were admitted to the intensive care unit, and 4 received
mechanical ventilation. All 4 patients who received mechanical
ventilation died, and 1 patient who died had not been admitted
to the intensive care unit (the 1 patient who was not admitted
to the intensive care unit received ribavirin and IVIG, and the
other 4 patients who died received ribavirin, IVIG, and paliv-
izumab). Overall, lower RTI occurred more frequently in pa-
tients with SID than in patients with MID ( ).Pp .068
RSV-attributable mortality. RSV-attributable mortality
was 18% (6 patients died). Among 6 patients who died, risk
factors for mortality were lower RTI at diagnosis in 5 patients
( ), 2 SID criteria in 6 patients ( ), 3 SIDPp .01 Pp .046
criteria in 4 patients ( ), and preengraftment in 3Pp .025
( ). Only 1 of 6 patients with SID who received riba-Pp .012
virin, IVIG, and palivizumab treatment for upper RTI died,
whereas 3 of 6 patients treated for lower RTI died ( ).Pp .16
RSV load in serial nasal secretions. We observed RSV loads
in serial nasal secretions of 19 patients treated with oral riba-
virin, 11 of whom had upper RTI (6 patients with MID and 5
with SID) and 8 of whom had lower RTI (1 with MID and 7
with SID) (figure 2). Median RSV load at diagnosis was 6.52
log10 copies/mL (range, 3.8–7.7 log10 copies/mL). Viral shedding
in nasal aspirate specimens remained detectable by RT-PCR for
7–28 days. A 12 log10 copies/mL decrease in RSV load was
observed in 11 (58%) of 19 patients within 7 days after initi-
ation of treatment, and no progression to lower RTI or death
occurred. Another 6 (32%) of 19 patients had 12 log10 copies/
mL decrease in RSV load within 14 days after diagnosis; lower
RTI occurred in 2 patients, and 1 patient died. One of 19
patients died on day 20. Duration of shedding was not asso-
ciated with site of infection, severity of immunodeficiency, RSV
subtype, or treatment modalities. However, symptoms lasted
longer in patients with SID than in patients with MID (Pp
, by Mann-Whitney U test) (figure 3A), and duration of.002
viral shedding correlated with the duration of symptoms in
patients with SID but exceeded the duration of symptoms in
patients with MID ( ; by Wilcoxon test) (figure 3B).Pp .027
Drug-related adverse events. Ribavirin (1800 mg per day)
was given to 19 of 25 treated patients. Transfusion-dependent
reversible hemolysis occurred in 5 patients (26%). In 1 patient
with RSV infection prior to HSCT and preexisting liver damage,
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Figure 3. Duration of respiratory syncytial virus shedding and symp-
toms. A, Duration of symptoms. Box plots of patients with severe im-
munodeficiency (SID; ) and patients with moderate immunodefi-np 7
ciency (MID; ; , by Mann-Whitney U test). B, Duration ofnp 8 Pp .04
respiratory syncytial virus shedding and symptoms. Patients with SID
( ; , by Wilcoxon rank sum test) are represented by whitenp 7 Pp .18
diamonds, and patients with MID ( ; , by Wilcoxon ranknp 8 Pp .027
sum test) are represented by black diamonds.
the bilirubin level increased from 100 to 150 mmol/L within 7
days after initiation of treatment. Ribavirin therapy was dis-
continued, but the bilirubin level remained elevated. Liver bi-
opsy revealed histologic characteristics that were compatible
with drug-induced liver damage; thus, we cannot exclude an
association with ribavirin. No adverse effects occurred in as-
sociation with IVIG and palivizumab therapy.
DISCUSSION
RSV is a significant pathogen in patients with hematological
diseases, but diagnosis, management, and outcome of RSV in-
fection are subjects of considerable uncertainty. With regard to
diagnosis, we found that RSV-specific RT-PCR is more sensitive
than culture and antigen testing in the clinical routine. The
RSV loads associated with positive culture and antigen test
results were 6.9 log10 copies/mL and 7.3 log10 copies/mL, re-
spectively, with a threshold of5.32 log10 copies/mL and5.56
log10 copies/mL, respectively. Only 2 of 39 studies reported the
use of RSV RT-PCR in patients with hematological diseases
[19, 20]. Therefore, the incidence of RSV infection and the risk
of nosocomial transmission may have been underestimated.
Virus isolation requires 3–5 days and dedicated laboratory ex-
pertise but remains the only alternative for detecting respiratory
viruses not covered by molecular techniques. RSV antigen test-
ing requires !4 h but detects less then one-third of the RT-
PCR–positive cases. Thus, antigen testing could play a role for
patients shedding RSV at high levels, to trigger infection-control
measures when RSV RT-PCR is not readily available. We con-
clude that RSV RT-PCR with a turnaround time of !24 h in
a quantitative format represents an asset in routine testing and
in future studies of patients with hematological diseases.
With regard to management, we report, to our knowledge,
the largest number of patients treated with oral ribavirin. Of
25 patients, 16 were seen in an outpatient context. The maximal
dosage of oral ribavirin (1800 mg per day) was generally well
tolerated. Hemolysis was observed in 5 cases and was readily
controlled by blood transfusions. Because of heterogeneous
therapy combinations, small sample size, and the retrospective
context, we are unable to provide a conclusion regarding
whether oral ribavirin therapy affected outcome. However, 2
considerations suggest that oral ribavirin therapy is probably
comparable to aerosolized ribavirin therapy. First, analysis of
serial nasal secretions from 19 patients treated with oral riba-
virin revealed a decrease in RSV load of 2 log10 copies/mL within
7 days after treatment initiation in 58% of the patients and
within 14 days after treatment initiation in 90% of the patients.
Boeckh et al. [10] reported a mean decrease in RSV load of
0.75 log10 copies/mL at 10 days after treatment initiation in 9
patients with RT-PCR–positive RSV infection and upper RTI
who were treated with aerosolized ribavirin, whereas 5 un-
treated patients had an increase in RSV load of 0.5 log10, to
1.26 log10 copies/mL. Second, rates of disease progression and
mortality in our study are comparable to those in studies using
aerosolized ribavirin.
Treatment with the neutralizing IgG antibody palivizumab,
in addition to ribavirin, was only to be considered for patients
with SID and upper RTI, with the underlying rationale being
to moderate progression to lower RTI. Although IgG may not
modify upper RTI, transudation of IgG in the lower respiratory
tract might reduce RSV replication and ameliorate the course
of infection in patients with SID. In patients with SID who
have established lower RTI, pavilizumab administration was
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deemed to be ineffective but was left to the discretion of the
treating physician. Of 6 patients with SID and upper RTI who
received a combination treatment with palivizumab, 1 patient
(16%) died, compared with 4 (57%) of 7 patients with SID
and lower RTI who received such treatment. Although these
data emphasize the role of lower RTI, no conclusion on paliv-
izumab efficacy can be made. Our results are comparable to
the only other study investigating 15 HSCT recipients using
aerosolized ribavirin in combination with palivizumab [15]. In
that study, 3 patients with upper RTI recovered without pro-
gression to lower RTI, and 17% of patients with lower RTI
died, but the SID status is not known [15].
With regard to outcome, we observed an RSV-attributable
mortality rate of 18%, which is in the lower range of rates in
the literature [1, 21, 22]. Lower RTI was a significant risk factor
for a poor outcome ( ). Mortality was increased duringPp .01
the preengraftment period, indicating that the risk was not
uniform but likely depended on the immunologic vulnerability.
To approximate the contribution of the “net state of immu-
nosuppression,” we developed a simple scheme to identify pa-
tients with SID and MID. Patients with 2 SID criteria had a
significantly higher risk for mortality. The overall better out-
come in patients with MID suggests that the simple scheme of
MID and SID could balance against overtreatment of patients
who received a diagnosis on the basis of more-sensitive meth-
ods, such as RT-PCR. Clearly, SID criteria warrant further val-
idation and, possibly, refinement in larger, preferably multi-
center studies.
After reviewing the literature, we could identify 39 articles
with 780 RSV-infected patients from 1981 through 2007 (table
3). With the exception of one study, all were uncontrolled, and
most were retrospective case series. Testing by culture was used
in 34 of 39 studies, direct fluorescence was used in 19, antigen
testing was used in 16, and RT-PCR was used in only 2. Of
the 780 RSV-infected patients, 462 patients had upper RTI, and
263 had lower RTI at RSV diagnosis. Aerosolized ribavirin was
administered to 337 patients, intravenous ribavirin was given
to 24, and oral ribavirin was given to 4. Both aerosolized and
intravenous ribavirin were given to 15 patients. IVIG was ad-
ministered to 163 patients, RSV-specific immunoglobulin was
given to 80, and palivizumab was given to 15. Progression to
lower RTI occurred in 174 (38%) of 462 patients. Upper RTI
progressed to lower RTI in 30 (32%) of 95 patients who were
treated with ribavirin. Upper RTI progressed to lower RTI in
76 (68%) of 112 untreated patients, suggesting that early treat-
ment might reduce progression to lower RTI. RSV-attributable
mortality was 18% among all 780 patients and 32% among 437
patients with lower RTI. Mortality rates decreased over the
years, from 50%–80% to 0%–30% within the same health care
centers [2, 8, 21, 22]. This may have occurred because of in-
creased awareness of RSV infection in hematology wards, earlier
and more-sensitive diagnostic testing, and possible inclusion of
patients with a milder course of infection. The role of treatment
is difficult to evaluate. In patients with lower RTI, death oc-
curred for 39 (38%) of 102 patients reported as treated with
aerosolized ribavirin, 50 (43%) of 116 patients treated with the
combination of ribavirin and IVIG, 18 (64%) of 28 patients
treated with intravenous ribavirin, and 15 (42%) of 36 un-
treated patients. The difference in outcome among these pa-
tients seems to be associated less with the efficacy of treatment
than with the disease state of the patient. Presumably, patients
treated with intravenous ribavirin had more-advanced disease
than did the others. In 6 studies, the preengraftment period
was associated with progression to lower RTI and RSV mor-
tality. Our study independently confirms preengraftment as a
risk factor and points to the potential relevance of the SID
criteria.
In conclusion, RSV infection has a significant impact on
morbidity and mortality among patients with hematological
diseases who have SID. Duration of shedding of RSV coincides
with the duration of symptoms in patients with SID but exceeds
the duration of the symptomatic phase in patients with MID.
RSV RT-PCR is currently the most powerful tool for diagnosis,
infection-control measures, and follow-up. Larger, multicenter
studies are needed to evaluate the role of SID criteria and of
ribavirin-based interventions in this patient population.
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